XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib

BACKGROUND: PARP inhibitor (PARPi) monotherapy is a new strategy in BRCA germ-line deficient triple negative breast cancer (TNBC). However, not all patients respond, and the development of resistance limits the use of PARPi monotherapy. Therefore, the development of alternative synthetic lethality s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ther Adv Med Oncol
Autors principals: Ali, Reem, Alblihy, Adel, Toss, Michael S., Algethami, Mashael, Al Sunni, Rabab, Green, Andrew R., Rakha, Emad A., Madhusudan, Srinivasan
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7758562/
https://ncbi.nlm.nih.gov/pubmed/33425022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920974201
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars